-
Something wrong with this record ?
Process performance and product quality in an integrated continuous antibody production process
DJ. Karst, F. Steinebach, M. Soos, M. Morbidelli,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27497430
DOI
10.1002/bit.26069
Knihovny.cz E-resources
- MeSH
- Bioreactors MeSH
- Cell Culture Techniques methods MeSH
- CHO Cells MeSH
- Cricetulus MeSH
- Cricetinae MeSH
- Antibodies, Monoclonal analysis isolation & purification metabolism MeSH
- Perfusion methods MeSH
- Protein Isoforms chemistry MeSH
- Protein Aggregates MeSH
- Recombinant Proteins analysis isolation & purification metabolism standards MeSH
- Animals MeSH
- Check Tag
- Cricetinae MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Continuous manufacturing is currently being seriously considered in the biopharmaceutical industry as the possible new paradigm for producing therapeutic proteins, due to production cost and product quality related benefits. In this study, a monoclonal antibody producing CHO cell line was cultured in perfusion mode and connected to a continuous affinity capture step. The reliable and stable integration of the two systems was enabled by suitable control loops, regulating the continuous volumetric flow and adapting the operating conditions of the capture process. For the latter, an at-line HPLC measurement of the harvest concentration subsequent to the bioreactor was combined with a mechanistic model of the capture chromatographic unit. Thereby, optimal buffer consumption and productivity throughout the process was realized while always maintaining a yield above the target value of 99%. Stable operation was achieved at three consecutive viable cell density set points (20, 60, and 40 × 106 cells/mL), together with consistent product quality in terms of aggregates, fragments, charge isoforms, and N-linked glycosylation. In addition, different values for these product quality attributes such as N-linked glycosylation, charge variants, and aggregate content were measured at the different steady states. As expected, the amount of released DNA and HCP was significantly reduced by the capture step for all considered upstream operating conditions. This study is exemplary for the potential of enhancing product quality control and modulation by integrated continuous manufacturing. Biotechnol. Bioeng. 2017;114: 298-307. © 2016 Wiley Periodicals, Inc.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017114
- 003
- CZ-PrNML
- 005
- 20180516110505.0
- 007
- ta
- 008
- 180515s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/bit.26069 $2 doi
- 035 __
- $a (PubMed)27497430
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Karst, Daniel J $u Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, Zurich CH-8093, Switzerland.
- 245 10
- $a Process performance and product quality in an integrated continuous antibody production process / $c DJ. Karst, F. Steinebach, M. Soos, M. Morbidelli,
- 520 9_
- $a Continuous manufacturing is currently being seriously considered in the biopharmaceutical industry as the possible new paradigm for producing therapeutic proteins, due to production cost and product quality related benefits. In this study, a monoclonal antibody producing CHO cell line was cultured in perfusion mode and connected to a continuous affinity capture step. The reliable and stable integration of the two systems was enabled by suitable control loops, regulating the continuous volumetric flow and adapting the operating conditions of the capture process. For the latter, an at-line HPLC measurement of the harvest concentration subsequent to the bioreactor was combined with a mechanistic model of the capture chromatographic unit. Thereby, optimal buffer consumption and productivity throughout the process was realized while always maintaining a yield above the target value of 99%. Stable operation was achieved at three consecutive viable cell density set points (20, 60, and 40 × 106 cells/mL), together with consistent product quality in terms of aggregates, fragments, charge isoforms, and N-linked glycosylation. In addition, different values for these product quality attributes such as N-linked glycosylation, charge variants, and aggregate content were measured at the different steady states. As expected, the amount of released DNA and HCP was significantly reduced by the capture step for all considered upstream operating conditions. This study is exemplary for the potential of enhancing product quality control and modulation by integrated continuous manufacturing. Biotechnol. Bioeng. 2017;114: 298-307. © 2016 Wiley Periodicals, Inc.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a monoklonální protilátky $x analýza $x izolace a purifikace $x metabolismus $7 D000911
- 650 _2
- $a bioreaktory $7 D019149
- 650 _2
- $a CHO buňky $7 D016466
- 650 _2
- $a buněčné kultury $x metody $7 D018929
- 650 _2
- $a křečci praví $7 D006224
- 650 _2
- $a Cricetulus $7 D003412
- 650 _2
- $a perfuze $x metody $7 D010477
- 650 _2
- $a proteinové agregáty $7 D066329
- 650 _2
- $a protein - isoformy $x chemie $7 D020033
- 650 _2
- $a rekombinantní proteiny $x analýza $x izolace a purifikace $x metabolismus $x normy $7 D011994
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Steinebach, Fabian $u Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, Zurich CH-8093, Switzerland.
- 700 1_
- $a Soos, Miroslav $u Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, Zurich CH-8093, Switzerland. Department of Chemical Engineering, University of Chemistry and Technology, Technicka 5, Prague 166 28, Czech Republic.
- 700 1_
- $a Morbidelli, Massimo $u Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, Zurich CH-8093, Switzerland.
- 773 0_
- $w MED00000795 $t Biotechnology and bioengineering $x 1097-0290 $g Roč. 114, č. 2 (2017), s. 298-307
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27497430 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180516110640 $b ABA008
- 999 __
- $a ok $b bmc $g 1300738 $s 1013954
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 114 $c 2 $d 298-307 $e 20160817 $i 1097-0290 $m Biotechnology and bioengineering $n Biotechnol Bioeng $x MED00000795
- LZP __
- $a Pubmed-20180515